A Phase 3 interventional study of GSK573719/GW642444 125/25mcg and GSK573719 125mcg in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 157 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-29.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 2nd largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 8th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:
Western University, Canada · Sites in Canada
Ages 50–85
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
National Institute of Respiratory Diseases, Mexico · Sites in Mexico
Ages 35–85 · Women only
By country, each count listing its studies:
GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,493 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 131 across the 43 interventional studies. Of the 37 that completed or were terminated, 25 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 43 have an industry lead sponsor. The 9 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline: 7 open now, 8 under way, 5 of them phase 3. Of 264 finished, 141 (53%) have results posted.
Among the 276 studies in Pulmonary Disease, Chronic Obstructive by GlaxoSmithKline, this one is the 12th largest by enrollment of the 236 interventional ones that give a count, is one of 26 that started in 2011, is one of 65 in phase 3, and was the 104th registered.
GlaxoSmithKline’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2000.
2 of the studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07133880University of Tennessee Graduate School of MedicineCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators | 2026-12-01 |
| NCT07192016Western University, Canada129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 276 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).
This is a 24-week, phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Eligible subjects will be randomized to GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, and placebo treatment groups in a 3:3:3:2 ratio such that of the planned 1463 total number of randomized subjects approximately 399 subjects will be randomized to each active treatment group and 266 subjects will be randomized to placebo. All treatments will be administered once-daily in the morning by inhalation using a Novel Dry Powder Inhaler (Novel DPI).
There will be a total of 9 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 7 to 14 day run-in period followed by a 24-week treatment period. Clinic visits will be at Screening, Randomization (Day 1), Day 2, after 4, 8, 12, 16, and 24-weeks of treatment, and 1 day after the Week 24 Visit (also referred as Treatment Day 169). A follow-up contact for adverse assessment will be conducted by telephone approximately 7 days after Visit 9 or the Early Withdrawal Visit. The total duration of subject participation, including follow-up will be approximately 27 weeks. All subjects will be provided with albuterol/salbutamol for use on an "as-needed" basis throughout the run-in and study treatment periods.
At screening, pre-bronchodilator spirometry testing will be followed by post-albuterol/salbutamol spirometry testing. Post-albuterol/salbutamol FEV1 and FEV1/FVC values will be used to determine subject eligibility. To further characterize bronchodilator responsiveness, post-ipratropium testing will be conducted following completion of post-albuterol/salbutamol spirometry.
Spirometry will be conducted at each post-randomization clinic visit. Six hour post-dose serial spirometry will be conducted at Visits 2, 4, 6, and 8. Trough spirometry will be obtained 23 and 24 hours after the previous day's dose of blinded study medication at Visits 3 to 9. All subjects will be provided with an electronic diary (eDiary) for completion daily in the evening throughout the run-in and treatment periods. Subjects will use the eDiary to record dyspnea scores using the Shortness of Breath with Daily Activities instrument (SOBDA), daily use of supplemental albuterol/salbutamol as either puffs/day from a metered-dose inhaler (MDI) and/or nebules used per day, and any healthcare contacts related to COPD.
Additional assessments of dyspnea will be obtained using the Baseline and Transition Dyspnea Index (BDI/TDI) which is an interviewer based instrument. At Visit 2, the severity of dyspnea at baseline will be assessed using the BDI. At subsequent visits (Visits 4, 6, and 8) change from baseline will be assessed using the TDI. Disease specific health status will be evaluated using the subject-completed St. George's Respiratory Questionnaire (SGRQ). The SGRQ will be completed at Visits 2, 4, 6, and 8. Administration of the SGRQ and BDI/TDI should be done prior to spirometry testing.
The occurrence of adverse events will be evaluated throughout the study beginning at Visit 2. SAEs will be collected over the same time period as for AEs. However, any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact.
Additional safety assessments of vital signs (blood pressure and pulse rate), 12-lead ECGs and standard clinical laboratory tests (hematology and chemistry) will be obtained at selected clinic visits. Blood samples for population pharmacokinetic analyses will be obtained.
At selected study sites, a subset of approximately 198 subjects will perform 24-hour serial spirometry during the study for evaluation of lung function over the dosing period. In conjunction with the serial spirometry, this subset of subjects will also perform 24 hour Holter monitoring and provide blood samples for PK analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
125/25mcg
Drug: GSK573719/GW642444 125/25mcg
125mcg
Drug: GSK573719 125mcg
25mcg
Drug: GW642444 25mcg
Placebo
Drug: Placebo only
125/25mcg
Also known as: umeclidinium bromide/vilanterol trifenatate
125mcg
Also known as: umeclidinium bromide
25mcg
Also known as: vilanterol trifenatate
Placebo
Also known as: placebo
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.
Time frame: Baseline and Day 169
Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24)
Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.
Time frame: Day 168 (Week 24)
Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.
Time frame: Baseline and Day 168
Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24
The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.
Time frame: Baseline and Week 24
| Milestone | Placebo | UMEC 125 µg QD | VI 25 µg QD | UMEC/VI 125/25 µg QD |
|---|---|---|---|---|
| Started | 275 | 407 | 404 | 403 |
| Completed | 183 | 312 | 298 | 325 |
| Not completed | 92 | 95 | 106 | 78 |
| Withdrew: Adverse event | 17 | 24 | 25 | 18 |
| Withdrew: Lack of efficacy | 44 | 38 | 37 | 24 |
| Withdrew: Protocol violation | 4 | 3 | 11 | 5 |
| Withdrew: Met protocol- defined stopping criteria | 16 | 15 | 14 | 13 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 | 3 |
| Withdrew: Withdrawal by subject | 11 | 13 | 18 | 15 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.
| Liters | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg |
|---|---|---|---|---|
| Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) | -0.031 ± 0.0153 | 0.129 ± 0.0119 | 0.093 ± 0.0121 | 0.207 ± 0.0119 |
Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.
| Scores on a scale | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg |
|---|---|---|---|---|
| Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24) | 0.8 ± 0.20 | 1.2 ± 0.16 | 1.3 ± 0.16 | 1.8 ± 0.15 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.
| Liters | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg |
|---|---|---|---|---|
| Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168 | -0.018 ± 0.0150 | 0.160 ± 0.0118 | 0.127 ± 0.0119 | 0.269 ± 0.0118 |
The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.
| Scores on a scale | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg |
|---|---|---|---|---|
| Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24 | -0.07 ± 0.038 | -0.15 ± 0.029 | -0.10 ± 0.029 | -0.22 ± 0.029 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to 24 weeks).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 17/275 (6.2%) | 63/275 (22.9%) |
| UMEC 125 µg | — | 22/407 (5.4%) | 97/407 (23.8%) |
| VI 25 µg | — | 20/404 (5%) | 113/404 (28%) |
| UMEC/VI 125/25 µg | — | 23/403 (5.7%) | 102/403 (25.3%) |
| Event | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg |
|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 8/275 | 4/407 | 3/404 | 5/403 |
| PneumoniaInfections and infestations | 4/275 | 2/407 | 0/404 | 3/403 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/275 | 0/407 | 1/404 | 2/403 |
| Acute myocardial infarctionCardiac disorders | 0/275 | 1/407 | 2/404 | 0/403 |
| Atrial fibrillationCardiac disorders | 0/275 | 2/407 | 1/404 | 0/403 |
| Ventricular extrasystolesCardiac disorders | 0/275 | 2/407 | 0/404 | 0/403 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/275 | 0/407 | 0/404 | 0/403 |
| Crohn's diseaseGastrointestinal disorders | 1/275 | 0/407 | 0/404 | 0/403 |
| IleusGastrointestinal disorders | 1/275 | 0/407 | 0/404 | 0/403 |
| Small intestinal obstructionGastrointestinal disorders | 1/275 | 0/407 | 0/404 | 0/403 |
| Event | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 32/275 | 37/407 | 55/404 | 47/403 |
| HeadacheNervous system disorders | 31/275 | 37/407 | 41/404 | 41/403 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/275 | 15/407 | 18/404 | 29/403 |
| Back painMusculoskeletal and connective tissue disorders | 13/275 | 17/407 | 10/404 | 10/403 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 9/275 | 5/407 | 10/404 | 4/403 |
| PyrexiaGeneral disorders | 7/275 | 9/407 | 9/404 | 13/403 |
| Age, Continuous(Years) | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg | Total |
|---|---|---|---|---|---|
| Mean | 62.2 ± 8.53 | 63.1 ± 8.48 | 62.8 ± 8.80 | 63.4 ± 8.08 | 62.9 ± 8.47 |
| Sex: Female, Male(Participants) | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg | Total |
|---|---|---|---|---|---|
| Female | 100 | 137 | 139 | 139 | 515 |
| Male | 175 | 270 | 265 | 264 | 974 |
| Race/Ethnicity, Customized(Participants) | Placebo | UMEC 125 µg | VI 25 µg | UMEC/VI 125/25 µg | Total |
|---|---|---|---|---|---|
| African American/African Heritage | 9 | 4 | 7 | 4 | 24 |
| American Indian or Alaska Native | 0 | 0 | 1 | 1 | 2 |
| Asian - Central/South Asian Heritage | 0 | 0 | 1 | 0 | 1 |
| Asian - Japanese Heritage | 13 | 21 | 21 | 19 | 74 |
| Asian - South East Asian Heritage | 14 | 19 | 20 | 20 | 73 |
| White - Arabic/North African Heritage | 1 | 2 | 1 | 0 | 4 |
| White - White/Caucasian/European Heritage | 237 | 361 | 353 | 359 | 1310 |
| Mixed Race | 1 | 0 | 0 | 0 | 1 |
Showing the first 100 of 157 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2011, a primary completion of Mar 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK573719 · Vilanterol
Pulmonary Disease, Chronic Obstructive →